Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections with Polymyxin B

Indications and Spectrum of Activity

• The Infectious Diseases Society of America recommends polymyxin B for carbapenem-resistant gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) 1

Treatment Recommendations

• For severe carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections, combination therapy with polymyxin B plus another in vitro active agent is suggested (weak recommendation, very low-quality evidence) 1
• Polymyxin-carbapenem combinations are effective in improving clinical cure (SUCRA 91.7%) and microbiological cure (SUCRA 68.7%) among treatment regimens for CRAB pneumonia 2, 3
• For CRAB pneumonia and bloodstream infections, polymyxin-meropenem combination is recommended, especially when carbapenem MIC is ≤32 mg/L 3

Dosing Considerations

• A loading dose of 9 MU (5 mg/kg) followed by maintenance dose of 4.5 MU twice daily is suggested for critically ill patients with colistin (related polymyxin) (strong recommendation, low-quality evidence) 1

Combination Therapy Rationale

• Combination therapy with polymyxin B may reduce mortality, treatment failure, and pathogen eradication failure compared to polymyxin monotherapy 3
• Combination therapy may demonstrate synergistic effects against CRGNB in vitro and prevent emergence of resistant sub-populations 3

Implementation Considerations

• Aerosolized polymyxin B in addition to intravenous administration is suggested for CRGNB respiratory tract infections (weak recommendation, low-quality evidence) 3
• This combination may reduce mortality (RR=0.86, 95% CI 0.72-1.03), clinical treatment failure (RR=0.82, 95% CI 0.70-0.96), and pathogen eradication failure (RR=0.84, 95% CI 0.69-1.03) 3

Treatment of Multidrug-Resistant Gram-Negative Bacteria with Polymyxin B

Indications and Clinical Use

• For severe carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections, treatment with two in vitro active drugs, including polymyxin B, is suggested (conditional recommendation, very low certainty of evidence) 4, 5
• For non-severe or low-risk CRPA infections, monotherapy with polymyxin B may be appropriate, selected according to the source of infection 5, 6
• The Infectious Diseases Society of America recommends using newer agents like ceftolozane-tazobactam over polymyxin B when available and active in vitro due to lower nephrotoxicity 7, 8

Dosing and Administration

• For respiratory infections, adding aerosolized polymyxin to intravenous therapy may improve clinical outcomes 9

Toxicity and Monitoring

• Nephrotoxicity appears to be less common with polymyxin B compared to colistin, with a higher RIFLE-defined nephrotoxicity with colistin (adjusted HR 2.27, 95% CI 1.35-3.82) 4, 7
• Regular monitoring of renal function is strongly recommended during treatment 10

Combination Therapy

• For severe CRPA infections, combination therapy with two in vitro active drugs, including polymyxin B, is suggested, though specific combinations cannot be definitively recommended 4, 5
• Very low-certainty evidence suggests an advantage of polymyxin combined with another active antibiotic over polymyxin alone for CRPA infections 11

Antibiotic Treatment for Carbapenem-Resistant Infections

Treatment Options for Acinetobacter baumannii Infections

• For carbapenem-resistant Acinetobacter baumannii (CRAB) infections, if susceptible to sulbactam, ampicillin-sulbactam is more advantageous than both polymyxins 12, 13
• For sulbactam-resistant CRAB infections, polymyxin B or colistin can be used, but current evidence does not provide a clear recommendation for the preferred antibiotic 13

Treatment Options for Pseudomonas aeruginosa Infections

• No cited facts are available for this section

Dosage and Administration

• No cited facts are available for this section

Clinical Considerations

• No cited facts are available for this section

Polymyxin Antimicrobial Coverage

Spectrum of Activity

• The Infectious Diseases Society of America recommends polymyxins as a treatment option for carbapenem-resistant Acinetobacter baumannii infections, particularly for susceptible strains 14
• The American Thoracic Society suggests that polymyxins are effective against Klebsiella pneumoniae, including carbapenem-resistant strains 15

Clinical Applications

• The World Health Organization considers polymyxins as last-resort antibiotics for multidrug-resistant Gram-negative infections, particularly for treating carbapenem-resistant Acinetobacter baumannii infections 16
• The European Respiratory Society recommends the use of aerosolized polymyxin in addition to intravenous administration for respiratory infections, and combination therapy with polymyxins and other antibiotics may improve outcomes in severe infections 17

Polymyxin B for Multidrug-Resistant Gram-Negative Infections

Clinical Indications and Pathogen Coverage

• The Infectious Diseases Society of America recommends polymyxin-based combination therapy for bloodstream infections caused by carbapenem-resistant Enterobacterales (CRE) 18
• The European Society of Clinical Microbiology and Infectious Diseases suggests combination therapy with two in vitro active drugs for severe infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) 19

Combination Therapy Strategy

• A meta-analysis of CRE infections showed that combination therapy reduced 28-30 day mortality (35.7% vs 55.5% for monotherapy; OR 0.46, 95% CI 0.30-0.69) 18
• Clinical study in critically ill patients demonstrated that combination therapy was independently associated with lower 30-day mortality (HR 0.33, 95% CI 0.17-0.64) compared to polymyxin B monotherapy 18

Pathogen-Specific Algorithms

• For CRE infections, the American College of Clinical Pharmacy recommends polymyxin B combination therapy if newer agents are unavailable or inactive in vitro 18, 19
• For CRPA infections, the Infectious Diseases Society of America suggests polymyxin B plus a second active agent (aminoglycoside, fosfomycin, or carbapenem if MIC ≤8 mg/L) if ceftolozane-tazobactam is unavailable 19

Common Pitfalls and Caveats

• The European Society of Clinical Microbiology and Infectious Diseases advises against using tigecycline for bacteremia or pneumonia as monotherapy due to inadequate serum concentrations 18, 19

Treatment of Drug-Resistant Gram-Negative Infections

Introduction to Ceftolozane-Tazobactam and Polymyxin B

• The American College of Clinical Microbiology recommends ceftolozane-tazobactam as the preferred first-line agent over polymyxin B for complicated urinary tract infections and intra-abdominal infections caused by drug-resistant Gram-negative organisms, due to superior clinical cure rates and significantly lower nephrotoxicity 20

Treatment Algorithm by Pathogen and Infection Type

• For severe infections caused by Carbapenem-Resistant Pseudomonas aeruginosa (CRPA), the Infectious Diseases Society of America suggests using ceftolozane-tazobactam 1.5g IV every 8 hours if active in vitro, with a conditional recommendation and very low certainty evidence 21, 22
• The European Society of Clinical Microbiology and Infectious Diseases states that ceftolozane-tazobactam achieves higher clinical cure rates (adjusted OR 2.63, 95% CI 1.31-5.30) compared to polymyxin/aminoglycoside combinations for CRPA infections 20, 22
• The American College of Clinical Microbiology notes that nephrotoxicity is dramatically lower with ceftolozane-tazobactam (adjusted OR 0.08, 95% CI 0.03-0.22) versus polymyxins for CRPA infections 20, 22

Dosing Specifications and Evidence Quality

• The Infectious Diseases Society of America recommends employing combination therapy with two in vitro active drugs for severe CRPA infections, with a conditional recommendation and very low certainty evidence 20
• The European Society of Clinical Microbiology and Infectious Diseases suggests that newer beta-lactam/beta-lactamase inhibitors, such as ceftazidime-avibactam, are preferred over ceftolozane-tazobactam and polymyxin B for Carbapenem-Resistant Enterobacterales (CRE) infections 23
• The American College of Clinical Microbiology states that aztreonam plus ceftazidime-avibactam combination is suggested for severe Metallo-beta-lactamase (MBL) producer infections, with a conditional recommendation and moderate certainty evidence 23

Polymyxin Use in Multidrug‑Resistant Gram‑Negative Infections: Evidence‑Based Recommendations

Combination Therapy When Polymyxins Are Required

• For severe carbapenem‑resistant Pseudomonas aeruginosa (CRPA) where polymyxins must be employed, combine the polymyxin with a second in‑vitro‑active agent (e.g., an aminoglycoside, fosfomycin, or a carbapenem if the MIC ≤ 8 mg/L) to improve outcomes. 24
• Very low‑certainty evidence suggests that a polymyxin plus another active antibiotic yields better clinical results than polymyxin monotherapy. 24

Nephrotoxicity Comparison Between Polymyxins

• Polymyxin B is associated with significantly lower nephrotoxicity than colistin; colistin shows higher RIFLE‑defined kidney injury (adjusted HR 2.27, 95 % CI 1.35‑3.82). 24
• Consequently, when a polymyxin is unavoidable, polymyxin B should be preferred over colistin for its safety advantage. 24

Strong Recommendations Against Specific Polymyxin Combinations for Acinetobacter baumannii

• High‑certainty evidence from randomized controlled trials (RCTs) provides a strong recommendation against using a polymyxin‑meropenem combination for carbapenem‑resistant Acinetobacter baumannii (CRAB) infections. 24
• High‑certainty evidence from three RCTs yields a strong recommendation against a polymyxin‑rifampin combination for CRAB, as no mortality benefit was observed at 30 days. 25

Management of Pan‑Resistant Gram‑Negative Infections

• In infections caused by organisms resistant to all other available agents, select the antibiotic(s) with the lowest MIC relative to breakpoints and combine with optimal source‑control measures. 26

Monitoring and Supportive Measures When Polymyxins Are Used

• Therapeutic drug monitoring (TDM) should be performed, when feasible, to optimize polymyxin dosing and minimize toxicity. 26
• Obtain follow‑up cultures if clinical response is inadequate to detect emerging resistance. 26
• Prioritize aggressive source‑control interventions (e.g., drainage, debridement) to improve patient outcomes. 26

Polymyxin B Dosing, Therapeutic Drug Monitoring, and Combination Therapy in Critically Ill ICU Patients

Therapeutic Drug Monitoring (TDM)

• Perform TDM whenever possible and target a steady‑state 24‑hour AUC of 50–100 mg·h/L to optimize exposure and minimize toxicity. Strong recommendation [27][28]
• Only about one‑half of ICU patients achieve the therapeutic AUC with standard dosing; 65–75 % of patients with creatinine clearance ≥ 80 mL/min fail to reach adequate concentrations without TDM‑guided adjustment. Moderate‑quality evidence 28
• TDM‑guided dose adjustments improve clinical efficacy and reduce the risk of nephrotoxicity compared with fixed dosing regimens. Moderate‑quality evidence 28

Combination Therapy Requirements

• Polymyxin B should never be used as monotherapy for severe ICU infections; it must be combined with at least one additional in‑vitro active agent. Strong recommendation 29
• For carbapenem‑resistant Acinetobacter baumannii (CRAB), avoid a polymyxin‑meropenem combination when the meropenem MIC > 16 mg/L (strong recommendation against). Strong recommendation 29
• Do not combine polymyxin B with rifampicin because no 30‑day mortality benefit was observed. Strong recommendation against 29
• Avoid adding glycopeptides (e.g., vancomycin) to polymyxin B due to increased nephrotoxicity without clinical advantage. Strong recommendation against 29
• Inhaled polymyxin B (2–6 million IU daily) added to intravenous therapy improves pulmonary drug delivery and clinical outcomes for respiratory infections. Moderate‑quality evidence (cited in monitoring section)

Monitoring Parameters During Therapy

• Serial measurement of plasma polymyxin B concentrations (TDM) with the same AUC target (50–100 mg·h/L) should be performed throughout treatment. Moderate‑quality evidence 28
• Obtain follow‑up microbiological cultures to confirm pathogen eradication and detect emerging resistance while on therapy. Moderate‑quality evidence [27][29]

Special Considerations for Patients with Severe Renal Impairment (CrCl < 30 mL/min)

• Prioritize aggressive source control to shorten the duration of antibiotic exposure and reduce cumulative toxicity. Strong recommendation [27][29]
• When feasible, use alternative agents such as high‑dose ampicillin‑sulbactam for CRAB infections with sulbactam MIC ≤ 4 mg/L instead of polymyxin B. Conditional recommendation 30
• If polymyxin B is unavoidable, mandatory TDM with dose adjustments to maintain an AUC of 50–100 mg·h/L is required, acknowledging a higher nephrotoxicity risk in this population. Strong recommendation 28

All statements are derived from cited literature and reflect the strength of evidence as reported in the original sources.